Alchemab Is Bringing A New Meaning To Patient-Centered Care

British-Bostonian Biotech Is Working Backwards To Explain Disease Resilience

12 Oct 2022

Alchemab Therapeutics sequences the antibodies of patients who prove especially resilient to hard-to-treat diseases to try and find therapeutic targets.

Depiction of an antibody — Alchemab is sequencing patients' B-cells in the hope of finding treatments for serious illnesses • Source: Shutterstock

At Alchemab Therapeutics the first step in the drug discovery journey starts not in a laboratory but with an individual person – not a scientist or researcher, but a patient. The biotech aims to target diseases across neurology and oncology through naturally occurring protective antibodies, mining the antibody receptors of individuals who are especially resistant to or have even recovered from serious illness to develop therapeutic products.

“Alchemab was founded on the idea that there are people who are resilient to disease, or perhaps just unusually well,...